Cost-Effectiveness of Pembrolizumab as First-Line Treatment in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in the United States by Bradley J. Monk, Sophie van Mens, Oliver Hale, Jennifer Boer, Frank van Hees, Shilpi Swami, Dominic Muston, Cumhur Tekin, Steve Keefe, Matthew Monberg

Get full text

Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer by Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori, Harushige Yokota, Ignace Vergote, Bradley J. Monk, Krishnansu S. Tewari, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Anne Paccaly, Kazuhiro Takehara, Tomoka Usami, Yoichi Aoki, Nao Suzuki, Yoichi Kobayashi, Yoshio Yoshida, Hidemichi Watari, Frank Seebach, Israel Lowy, Melissa Mathias, Matthew G. Fury, Ana Oaknin

Get full text

Use of individualized starting dose and niraparib hematologic adverse event management costs in ovarian cancer by Whitney S Graybill, Ignace Vergote, Bhavana Pothuri, Maarit Anttila, David M O’Malley, Domenica Lorusso, Ashley F Haggerty, Michel Fabbro, John K Chan, Florian Heitz, Lyndsay J Willmott, Ilan Bruchim, Ying Zhuo, Purificacion Estevez-Garcia, Bradley J Monk, Hannelore Denys, Anja Knudsen, Anna V Tinker, Luis Manso Sanchez, Diane Provencher, Maria Pilar Barretina-Ginesta, John Hartman, Donna V Booth, Antonio Gonzalez-Martin